Alnylam Pharmaceuticals, Inc. Equity-NMS: ALNY

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.
Powered by Vested Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly
Loading, Please wait...
Previous close :$262.16
Open :$257.14
Today's high :$259.16
Today's low :$235.57
52W low :$141.98
52W high :$304.39
EPS(TTM): :-2.19
Shares O/S :129.43 M
Market cap :30.51 B

Compare with Other Stocks

Stocks Price 1D PE Market Cap
Alnylam Pharmaceuticals, Inc. $235.74 -60.57% - 30.51B

Frequently Asked Questions

What is the share price of Alnylam Pharmaceuticals, Inc. today?

Alnylam Pharmaceuticals, Inc. (ALNY) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.